CureVac’s Independent Journey Concludes with BioNTech Acquisition

The final chapter has closed for CureVac as a publicly traded entity. The German biotech firm, once a beacon of hope from Tübingen, has been fully integrated into Mainz-based BioNTech as a wholly-owned subsidiary. This organizational restructuring was finalized on January 6, 2026, following a successful exchange offer, marking an irreversible departure for investors as trading in the stock has been suspended.

The merger concludes a period defined by significant operational headwinds. While CureVac’s shares posted a 41% gain in their final year of trading, outperforming the S&P 500’s 18.2% rise, this surge was primarily driven by the approximately 55% takeover premium. Fundamentally, the company faced a stark 92% revenue decline from its Read more...